ipamorelin mastery course
Unit 10 of 11

the regulatory landscape

no approval anywhere, off the 503A list, prohibited by WADA

a 25-year regulatory arc that ends in restriction

Ipamorelin has never been approved by FDA, EMA, MHRA, TGA, Health Canada, or PMDA. Novo Nordisk discontinued development in the early-to-mid 2000s. Helsinn discontinued after the negative Beck 2014 ileus trial. In September 2023 the FDA placed ipamorelin into Category 2 of the interim 503A bulks list, effectively prohibiting compounding. Litigation settled in 2024 and the FDA Pharmacy Compounding Advisory Committee reviewed it. On 29 October 2024 PCAC voted against adding ipamorelin to the 503A bulks list. It remains ineligible for legal compounding in the United States. WADA prohibits it at all times under section S2.2.2.

OCT 2024

current regulatory status

as of October 2024, the FDA Pharmacy Compounding Advisory Committee voted against ipamorelin's eligibility for 503A compounding. it is not FDA-approved and has no Russian or EU regulatory authorization. all current consumer access is via gray-market research-chemical channels.

jurisdictional map

click any jurisdiction for the approval status, key date, current legal context, and source citation. arrow keys cycle, Enter pins.

jurisdictional status map

key terms

tap to expand.

5503A compoundingregulatory
section 503A of the Federal Food, Drug, and Cosmetic Act -- the law governing traditional pharmacy compounding from bulk substances. ingredients eligible for 503A compounding must appear on an FDA-approved bulks list. ipamorelin was not added to that list after the PCAC vote, leaving it ineligible.
PPCACFDA committee
Pharmacy Compounding Advisory Committee -- the FDA advisory body that reviews substances nominated for the 503A bulks list. its votes are advisory but the FDA almost always follows them. on 29 October 2024 it voted against ipamorelin, ibutamoren, L-theanine, and kisspeptin-10.
CCategory 2FDA designation
an FDA classification for bulk drug substances flagged as potentially presenting significant safety risks. ipamorelin was placed in Category 2 of the interim 503A list in September 2023, effectively prohibiting its use in compounding pending review.
NNDAFDA process
New Drug Application -- the regulatory submission that brings a small-molecule or peptide drug to FDA approval. ipamorelin has never been submitted as an NDA; both Novo and Helsinn discontinued before approval.
WWADA S2anti-doping
section S2 of the World Anti-Doping Agency Prohibited List covers peptide hormones, growth factors, related substances, and mimetics. subsection S2.2.2 specifically names growth-hormone-secretagogues, including ipamorelin, anamorelin, capromorelin, ibutamoren, lenomorelin/ghrelin, macimorelin, and tabimorelin.
Rresearch-onlycommercial label
the standard "not for human use, for research only" labeling on grey-market peptide product. this label does not confer legal status as a drug, supplement, or device. selling such product for human use is the sale of an unapproved new drug under FDCA Sec. 301(d) / Sec. 505.

what "research only" actually means -- the simple version

the legal status everyone glosses over.

Ipamorelin in the United States is sold under a "not for human use, research only" label. That phrase does a lot of work in the marketing -- it sounds like a regulatory category. It is not. The "research only" label does not make a product a legal supplement, a legal drug, or a legal medical device. It is a disclaimer the seller writes on the bottle to argue that the sale is not for human consumption.

The FDA's position is straightforward: an unapproved peptide marketed for human use is an unapproved new drug under sections 301(d) and 505 of the Federal Food, Drug, and Cosmetic Act. The October 2024 PCAC vote against 503A inclusion closes the only legal compounding-pharmacy pathway. After PCAC, the only ways to legally encounter ipamorelin in the United States are inside an active clinical trial or under explicit research-use-only conditions in a registered research lab.

Outside the US, the picture is similar. No national regulator anywhere in the world has approved ipamorelin for any indication. WADA prohibits it for all athletes under its jurisdiction. The compound is widely available in practice, but practical availability and legal status are not the same thing.

Aadvanced: the 2023-2024 FDA timeline in detailregulatory
September 2023: FDA moved ipamorelin (and CJC-1295, sermorelin variants, AOD-9604, BPC-157, kisspeptin-10, others) into Category 2 of the interim 503A bulks list, effectively prohibiting use in 503A compounding pending review. 2023-2024: Evexias Health Solutions and Farmakeio Custom Compounding sued the FDA under the Administrative Procedure Act, challenging the lack of transparency in the Category 2 designations. September 2024: settlement -- FDA agreed to refer the disputed peptides to PCAC for public review. 29 October 2024: PCAC voted against adding ipamorelin (and ipamorelin acetate, ibutamoren, L-theanine, kisspeptin-10) to the 503A bulks list. ipamorelin is therefore ineligible for compounding in US 503A pharmacies. the underlying FDA briefing document (FDA-2024-N-4188) explicitly flags the absence of a positive efficacy RCT and the misuse of Gobburu 1999 in nominator materials as drivers of the negative vote.
advanced: WADA detection methodology and the 2026 threshold change
WADA-accredited labs detect ipamorelin and other GHS-class peptides by LC-MS/MS in plasma and urine, using selected-reaction-monitoring transitions optimized for the parent peptide and characteristic fragment ions. the 2026 Prohibited List lowered the detection threshold for the GHS class to 0.1 ng/mL, a meaningful improvement over earlier thresholds that allowed sub-therapeutic doses to evade detection. detection is grounds for sanction; the substance is prohibited at all times for all athletes under WADA jurisdiction, in and out of competition.
advanced: why Novo and Helsinn walked away
the widely-circulated explanation -- "business decision, not a safety signal" -- is consistent with the public record. Novo Nordisk's growth-hormone franchise (Norditropin) was already established; the AGHD market was modest; resources shifted to the diabetes and obesity programs that became the GLP-1 franchise. no safety or efficacy red flag has ever been published. Helsinn's walk-away followed the negative Beck 2014 result directly -- the trial missed its primary endpoint and the program had no other supported indication. caveat: absence of a published red flag is not the same as absence of an internal red flag. the underlying clinical-development data Novo Nordisk generated has never been released.
FDA PCAC 2024 vote -- current status box. on 29 October 2024 the FDA Pharmacy Compounding Advisory Committee voted against adding ipamorelin (and ipamorelin acetate) to the 503A bulks list. ipamorelin remains ineligible for legal compounding in the United States. the FDA briefing document for the vote (FDA-2024-N-4188) explicitly cited the absence of a positive efficacy RCT and the misuse of Gobburu 1999 in nominator materials.
WADA prohibition. ipamorelin is prohibited at all times -- in- and out-of-competition -- for all athletes under WADA jurisdiction under section S2.2.2 of the Prohibited List. detection is via LC-MS/MS; the 2026 threshold for the GHS class is 0.1 ng/mL. use is grounds for sanction regardless of dose, pattern, or stated rationale.

where this has been studied

the regulatory documents and the empirical evidence on gray-market product quality.

FDA PCAC briefing
FDA-2024-N-4188 -- the October 2024 Pharmacy Compounding Advisory Committee briefing document on ipamorelin and ipamorelin acetate. explicitly reviews the evidence base, flags the negative Beck 2014 trial and the misuse of Gobburu 1999, and documents the vote against 503A inclusion.
FDA 2023 Category 2
"Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" -- the September 2023 interim list move that placed ipamorelin into Category 2 and effectively prohibited compounding pending PCAC review.
WADA 2026 List
WADA "The 2026 Prohibited List" -- section S2.2.2 names ipamorelin alongside anamorelin, capromorelin, ibutamoren, lenomorelin, macimorelin, and tabimorelin. updated annually; detection threshold lowered to 0.1 ng/mL.
gray-market product QC
Vanhee et al. Drug Test Anal 2020 (PMID 32869497) -- retrospective analysis of seized cosmetic and food supplements containing growth-hormone-related peptides. documented the gray-market scale and the QC variability that follows from non-FDA-overseen manufacturing.